INDUSTRIALISATION
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
CONTRIBUTE
MEDIA PACK
Subscribe
INDUSTRIALISATION
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
CONTRIBUTE
MEDIA PACK
SEARCH
SEARCH
advanced search
Ophthalmic Drug Delivery
130
Issue No #130 March 2022
March 14th, 2022
Download PDF
Issue 130 - Mar 2022
Inside the magazine
EXPERT VIEW
Dr Yongdong Zhou
WHY GENE THERAPY IS PERFECT FOR TREATING OCULAR DISEASES
Yongdong Zhou discusses the applications, advantages and challenges of gene therapy in the ophthalmic sector.
INTERVIEW
Natalia Servol
Unither Pharmaceuticals
INTERVIEW: Natalia Servol, Unither Pharmaceuticals
In this interview, Natalia Servol, Head of Unither Pharmaceuticals’ Ophthalmic Business, speaks about the company's equipment for compounding and fill-finish of preservative-free products into multidose bottles, part of Unither’s unique and innovative preservative-free multidose offering for partners.
OCULAR
Rouven Kraus
Aero Pump
THE DEMAND FOR METERED DOSE EYE DROPS: A DOSE DELIVERY STUDY
Rouven Kraus discusses a dose delivery study comparing various delivery technologies designed to meet the demand for metered dose eye drops.
OCULAR
Justin Westendorf
Phillips Medisize
A CULTURE OF COLLABORATION INSPIRES INNOVATION AND LIFE-CHANGING THERAPIES
Justin Westendorf describes the company’s collaborative approach with a leader in ocular disease treatments to overcome technical and stakeholder challenges.
OCULAR
Alexandra Ritter
Aptar Pharma
AN EYE ON THE FUTURE OF PRESERVATIVE-FREE DROPS
Alexandra Ritter and Matthias Birkhoff discuss the importance of the regulatory support the company offers to its customers for preservative-free ophthalmic platforms in the face of increasingly stringent regulatory requirements from both the EU EMA and US FDA, and describe new opportunities and growing demand for a wider range of multidose preservative-free ophthalmic drug-device combinations, including for indications such as dry-eye and glaucoma.
OCULAR
Dr Harsh Patel
Celanese
SUSTAINED, CONTROLLED DRUG DELIVERY TO THE EYE
Harsh Patel, Cyonna Holmes and Brian Wilson consider the challenges and advances in sustained-release ocular drug delivery.
EARLY INSIGHT
Timo Kangastupa
Visionisti
A NEW PLATFORM FOR SUPRACHOROIDAL DRUG DELIVERY USING STANDARD NEEDLES
Timo Kangastupa discusses the potential of the suprachoroidal space for highly effective, specifically targeted drug delivery to the choroid and retina, and how Visionisti’s technology simplifies and standardises the procedure, enabling the use of standard commercially available needles for suprachoroidal delivery.
OCULAR
Dr Andrea Allmendinger
ten23 health
HOW TEN23 HEALTH IS MEETING DEVELOPMENTAL CHALLENGES FOR INTRAVITREAL PRODUCTS
Andrea Allmendinger and Hanns-Christian Mahler highlight new regulatory and quality requirements for intravitreal applications and discuss technical challenges during drug product technical development and manufacturing.
EARLY INSIGHT
Dr Eva M del Amo
University of Eastern Finland DrugTech
PHARMACOKINETIC MODELS: INDISPENSABLE TOOLS FOR OPHTHALMIC DRUG DEVELOPMENT
Eva del Amo presents an overview of pharmacokinetic models for ophthalmic drugs, and discusses the value of these models for future drug development in the sector.
EXPERT VIEW
Dr Jay S Duker
ENVISIONING NEW HORIZONS IN OCULAR DRUG DELIVERY
Jay S Duker discusses the history and future of ocular drug delivery, with a special focus on posterior segment diseases and the battle to overcome significant patient and caregiver burdens.
OCULAR
Dr Gautam Shetty
Congruence Medical Solutions
OPHTHALMIC INJECTION OF VISCOUS FORMULATIONS – WHY UNIQUE NEEDS REQUIRE A NOVEL DELIVERY APPROACH
Guatam Shetty and Richard Whelton outline the key considerations related to ophthalmic injection of viscous formulations and propose an innovative, user-validated and fully mechanical device-based solution.
EXPERT VIEW
Robert Lee
KEEPING UP WITH THE DEMAND FOR EFFECTIVE OPHTHALMIC DRUGS
Robert Lee explores the growth of the ophthalmic drug market and discuss the challenges that pharma companies may face when creating drugs to treat some of the most common ocular indications.
Top
